Answers are grounded in this paper and cite their sources.
Phase 2 trial finds improved outcomes with combined PD-1 and TIGIT blockade in first-line advanced gastroesophageal cancer, suggesting potential for enhanced therapy.
Background: Adding programmed cell death protein 1 (PD-1) inhibitors to chemotherapy confers a survival advantage in 1L GE cancers, yet long-term outcomes remain poor. Dual PD-1 and anti-T-cell immunoglobulin and ITM domain (TIGIT) blockade increases tumor specific CD8+T cells, resulting in potent antitumor activity.
No takes yet. Share an insight, caveat, or question.
Eylenstein et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: